Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Helius Medical Technologies ( (HSDT) ) just unveiled an update.
On September 18, 2025, Helius Medical Technologies closed a private placement offering, raising over $500 million with the potential to reach $1.25 billion upon full exercise of issued warrants. The funds will be used to implement a digital asset treasury strategy focused on acquiring SOL, the native cryptocurrency of the Solana blockchain, to serve as the company’s primary treasury reserve asset. The offering was led by Pantera Capital and Summer Capital, with participation from various investors. Additionally, Joseph Chee was appointed as Executive Chairman, and the company plans to leverage Solana’s architecture for growth in decentralized finance and broader on-chain activities.
The most recent analyst rating on (HSDT) stock is a Sell with a $21.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies is currently facing significant financial and operational challenges, as evidenced by its declining revenue, negative profitability, and poor cash flow. The technical analysis suggests mixed signals with short-term bullish momentum but long-term bearish trends. The company’s valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Helius Medical Technologies is a leading neurotech company in the medical device field, focusing on neurologic deficits using an orally applied technology platform that enhances the brain’s ability to engage compensatory mechanisms and promote neuroplasticity. The company’s first commercial product is the Portable Neuromodulation Stimulator.
Average Trading Volume: 742,350
Technical Sentiment Signal: Strong Sell
Current Market Cap: $24.51M
For a thorough assessment of HSDT stock, go to TipRanks’ Stock Analysis page.